BinDeBio is a leading biotechnology group dedicated to the development and commercialization of immune cell therapy for cancer treatment. Established in 2015, BinDeBio is supported by the Shenzhen government and has established extensive collaborations with the Chinese Academy of Sciences and various national authoritative hospitals. The company specializes in CAR-T and TCR-T immune cell technologies, which are internationally renowned.

BinDeBio has built a comprehensive immune therapy industry chain, including the production of clinical-grade intermediates and the bioengineering of clinical-grade cell preparation. This, along with partnerships with major hospitals and oncology rehabilitation centers, allows BinDeBio to offer a state-of-the-art platform for tumor treatment and rehabilitation, integrating the management of cancer treatment and recovery. BinDeBio's mission is to improve the quality of life for patients and extend their lifespan to the greatest extent possible.

With a commitment to research and development, BinDeBio is at the forefront of innovation in immune cell therapy